BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2546280)

  • 1. Functional assays for protein C activity and protein C inhibitor activity in plasma.
    Geiger M; White TM; Griffin JH
    Thromb Haemost; 1989 Feb; 61(1):86-92. PubMed ID: 2546280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies against the heparin-dependent protein C inhibitor suitable for inhibitor purification and assay of inhibitor complexes.
    Laurell M; Carlson TH; Stenflo J
    Thromb Haemost; 1988 Oct; 60(2):334-9. PubMed ID: 3217924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor.
    Shen L; Villoutreix BO; Dahlbäck B
    Thromb Haemost; 1999 Jul; 82(1):72-9. PubMed ID: 10456457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo.
    Orthner CL; Kolen B; Drohan WN
    Thromb Haemost; 1993 May; 69(5):441-7. PubMed ID: 8322267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment.
    Tabernero D; España F; Vicente V; Estellés A; Gilabert J; Aznar J
    Thromb Haemost; 1990 Jun; 63(3):380-2. PubMed ID: 2169656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
    Chan AK; Patel S; Male C; Berry LR; Mitchell LG
    Thromb Haemost; 2004 Feb; 91(2):238-47. PubMed ID: 14961149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional consequences of mutations in amino acid residues that stabilize calcium binding to the first epidermal growth factor homology domain of human protein C.
    Geng JP; Cheng CH; Castellino FJ
    Thromb Haemost; 1996 Nov; 76(5):720-8. PubMed ID: 8950780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-protein C interaction.
    Comp PC
    Nouv Rev Fr Hematol (1978); 1984; 26(4):239-42. PubMed ID: 6089102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competition of activated protein C and urokinase for a heparin-dependent inhibitor.
    Geiger M; Heeb MJ; Binder BR; Griffin JH
    FASEB J; 1988 Apr; 2(7):2263-7. PubMed ID: 3350241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A second plasma inhibitor of activated protein C: alpha 1-antitrypsin.
    van der Meer FJ; van Tilburg NH; van Wijngaarden A; van der Linden IK; Briët E; Bertina RM
    Thromb Haemost; 1989 Sep; 62(2):756-62. PubMed ID: 2554521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma.
    España F; Estelles A; Griffin JH; Aznar J
    Thromb Haemost; 1991 Jan; 65(1):46-51. PubMed ID: 1850876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis.
    Bangert K; Thorsen S
    Thromb Haemost; 2000 Aug; 84(2):299-306. PubMed ID: 10959704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
    Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
    J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
    Nishioka J; Ido M; Hayashi T; Suzuki K
    Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protein C omega-loop substitution Asn2Ile is associated with reduced protein C anticoagulant activity.
    Preston RJ; Morse C; Murden SL; Brady SK; O'Donnell JS; Mumford AD
    Br J Haematol; 2009 Mar; 144(6):946-53. PubMed ID: 19133979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
    Darras V; Thienpont M; Stump DC; Collen D
    Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma.
    Mewhort-Buist TA; Liaw PC; Patel S; Atkinson HM; Berry LR; Chan AK
    Thromb Res; 2008; 122(3):418-26. PubMed ID: 18206217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of circulating activated protein C in human plasma by immunoassays--enzyme levels are proportional to total protein C levels.
    Espana F; Zuazu I; Vicente V; Estellés A; Marco P; Aznar J
    Thromb Haemost; 1996 Jan; 75(1):56-61. PubMed ID: 8713780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
    Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.